Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Jyong Biotech Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2025
FY2025
Research and development
1.07
0.93
0.81
Selling and marketing
0.05
0.04
0.05
General and administrative
1.68
1.09
1.75
Operating expenses
2.8
2.06
2.61
Operating income
-2.8
-2.06
-2.61
Interest expense
0.76
1.04
2.54
Interest income
0.06
0.01
0.61
Other non-operating income
-1.6
-0.96
-2.06
Pre-tax income
-4.4
-3.02
-4.67
Net income
-4.4
-3.02
-4.67
EBITDA
-2.67
-1.94
-2.51
EPS, basic
-0.06
-0.04
-0.06
EPS, diluted
-0.06
-0.04
-0.06
Shares, basic (weighted)
71.6
71.6
73
Shares, diluted (weighted)
71.6
71.6
73
Balance sheet
FY2023
FY2025
FY2025
Cash and equivalents
1.74
0.1
1.18
Other current assets
0.11
0.85
Total current assets
0.21
15.5
Property, plant and equipment
3.05
3.09
Lease right-of-use assets
0.14
0.07
Other non-current assets
0.01
0.01
Total assets
6.37
20.8
Accounts payable
0
0
Accrued liabilities
1.2
1.04
Short-term debt
15.3
Total current liabilities
12.1
34.8
Lease liabilities
0.02
0.03
Other non-current liabilities
0.06
0.06
Total liabilities
42.9
45.7
Total debt
2.12
Paid-in capital
11.8
28.5
Retained earnings
-30.1
-33.1
-37.8
Treasury stock
-16.4
-16.4
Other comprehensive income
1.12
0.68
Shareholders' equity
-34.1
-36.5
-24.9
Total equity
-34.1
-36.5
-24.9
Total liabilities and equity
6.37
20.8
Shares outstanding
73.4
76
Cash flow statement
FY2023
FY2025
FY2025
Net income
-4.4
-3.02
-4.67
Depreciation and amortization
0.13
0.12
0.1
Change in payables
-0
0
-0
Cash from operations
-2.6
-3.62
-3.04
Purchases of investments
-16.9
Cash from investing
0.1
-13.5
Stock issued
17.8
Cash from financing
2.03
1.99
17.6
Exchange rate effect
-0.05
-0.01
-0.01
Net change in cash
-0.53
-1.64
1.08
Interest paid
0.1
0.22
0.34
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $2.03 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-34.4%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
226.4%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
2.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.45x
Current assets / current liabilities.
Quick ratio
0.03x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.03x
(Cash + short-term investments) / current liabilities.
Debt / assets
10.2%
Total debt / total assets.
Liabilities / assets
219.9%
Total liabilities / total assets.
Net debt
$946.0K
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.06
Net income per basic share, as reported (split-adjusted).
Operating cash flow per share
-$0.04
Cash from operations / diluted weighted shares.
Book value per share
-$0.33
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
Earnings yield
-3.0%
Net income / market cap (the inverse of P/E).
Was Jyong Biotech Ltd. profitable in fiscal 2025?
No. It reported a net loss of $4.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.